Tomas Hode active positions
| Companies | Position | Start | End |
|---|---|---|---|
Immunophotonics, Inc.
 Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | Director/Board Member | 2008-12-31 | - |
| Founder | 2008-12-31 | - | |
| President | - | - | |
| Chief Executive Officer | 2008-12-31 | - | |
| Missouri Biotechnology Association | Director/Board Member | - | - |
Career history of Tomas Hode
Training of Tomas Hode
| University of Stockholm | Doctorate Degree |
Statistics
International
| United States | 3 |
| Sweden | 2 |
Operational
| Director/Board Member | 2 |
| Chief Executive Officer | 1 |
| Founder | 1 |
Sectoral
| Health Technology | 2 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
Immunophotonics, Inc.
Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | Health Technology |
| Missouri Biotechnology Association |
- Stock Market
- Insiders
- Tomas Hode
- Experience
